CAJ | 학술논문

目的：研究牵牛子在二乙基亚硝胺( NDEA)诱发大鼠肝癌中的抑制作用。方法将大鼠分为正常对照组、模型对照组和牵牛子组,采用0.01% NDEA诱发模型对照组和牵牛子组大鼠肝癌90 d,牵牛子组在诱发癌的同时,用含6%牵牛子饲料按40 g·kg-1·d-1剂量喂养。停止诱发,继续喂养30 d后处死大鼠,观察大鼠肝脏的病理改变、肝表面癌结节数、肝质量、肝/体质量比以及血清中丙氨酸氨基转移酶( ALT)、γ-谷氨酰转肽酶(γ-GT)、碱性磷酸酶( ALP)的变化。利用单因素方差分析LSD法检验进行统计分析。结果正常对照组大鼠肝表面癌结节数为(0.0±0.0)个,肝质量为(9.87±1.30) g,肝/体质量比为(2.62±0.24)%,血清 ALT为(64.10±12.71) U·L-1,γ-GT为(0.80±0.42) U·L-1,ALP为(121.20±37.57) U·L-1。模型对照组大鼠肝表面癌结节数为(27.4±9.5)个,肝质量为(21.38±7.29) g,肝/体质量比为(5.82±2.31)%,血清ALT为(175.70±48.75) U·L-1,γ-GT为(41.80±15.38) U·L-1,ALP为(200.50±35.78) U·L-1。牵牛子组大鼠肝表面癌结节数为(8.6±5.3)个,肝质量为(13.91±3.55)g,肝/体质量比为(3.86±0.76)%,血清ALT为(113.10±45.35) U·L-1,γ-GT为(13.40±6.15) U·L-1,ALP为(155.80±30.26) U·L-1。结果显示,牵牛子组各项指标高于正常对照组,低于模型对照组,差异有统计学意义(P<0.01或P<0.05)。结论牵牛子能减轻NDEA对肝细胞的损伤,抑制NDEA诱发大鼠肝癌的过度生长。
목적：연구견우자재이을기아초알( NDEA)유발대서간암중적억제작용。방법장대서분위정상대조조、모형대조조화견우자조,채용0.01% NDEA유발모형대조조화견우자조대서간암90 d,견우자조재유발암적동시,용함6%견우자사료안40 g·kg-1·d-1제량위양。정지유발,계속위양30 d후처사대서,관찰대서간장적병리개변、간표면암결절수、간질량、간/체질량비이급혈청중병안산안기전이매( ALT)、γ-곡안선전태매(γ-GT)、감성린산매( ALP)적변화。이용단인소방차분석LSD법검험진행통계분석。결과정상대조조대서간표면암결절수위(0.0±0.0)개,간질량위(9.87±1.30) g,간/체질량비위(2.62±0.24)%,혈청 ALT위(64.10±12.71) U·L-1,γ-GT위(0.80±0.42) U·L-1,ALP위(121.20±37.57) U·L-1。모형대조조대서간표면암결절수위(27.4±9.5)개,간질량위(21.38±7.29) g,간/체질량비위(5.82±2.31)%,혈청ALT위(175.70±48.75) U·L-1,γ-GT위(41.80±15.38) U·L-1,ALP위(200.50±35.78) U·L-1。견우자조대서간표면암결절수위(8.6±5.3)개,간질량위(13.91±3.55)g,간/체질량비위(3.86±0.76)%,혈청ALT위(113.10±45.35) U·L-1,γ-GT위(13.40±6.15) U·L-1,ALP위(155.80±30.26) U·L-1。결과현시,견우자조각항지표고우정상대조조,저우모형대조조,차이유통계학의의(P<0.01혹P<0.05)。결론견우자능감경NDEA대간세포적손상,억제NDEA유발대서간암적과도생장。
Objective To study the inhibitory effect of Pharbitidis Semen on rat hepatoma induced by N-nitrosodiethylamine ( NDEA) . Methods SD rats were divided into normal control group, model control group and Pharbitidis Semen group. In model control group and Pharbitidis Semen group, 0. 01% NDEA was applied for 90 days to induce hepatoma, and rats in Pharbitidis Semen group concomitantly received feed containing 6% Pharbitidis Semen at the dosage of 40 g·kg-1 ·d-1 . Thirty days after the hepatoma inducement and Pharbitidis Semen administration, the rats were sacrificed to observe the pathological changes in liver, number of hepatoma nodules and liver weight. The changes of liver/body weight, serum alanine aminotransferase (ALT), γ-glutamyl transferase (γ-GT), and alkaline phosphatase (ALP) were compared. One-way ANOVA (LSD Test) was employed for statistical analysis. Results In the normal control group, the number of hepatoma nodules was 0. 0±0. 0, the liver weight was (9. 87±1. 30) g, the ratio of liver/body weight was (2. 62±0. 24)% and the level of serum ALT was (64. 10±12. 71) U·L-1,γ-GT was (0. 80± 0. 42) U·L-1, and ALP was (121. 20±37. 57) U·L-1. In the model control group, the number of hepatoma nodules was (27. 4±9. 5), the liver weight was (21. 38±7. 29) g, the ratio of liver/body weight was (5. 82±2. 31)%, the level of serum ALT was (175. 70±48. 75) U·L-1, γ-GT was (41. 80±15. 38) U·L-1, and ALP was (200. 50±35. 78) U·L-1. In the Pharbitidis Semen group, the number of hepatoma nodules was (8. 6± 5. 3), the liver weight was (13. 91±3. 55) g, the ratio of liver/body weight was (3. 86±0. 76)% and the level of serum ALT was (113.10±45.35) U·L-1, γ-GT was (13. 40± 6. 15) U·L-1, and ALP was (155. 80±30. 26) U·L-1. The results showed that all indices of Pharbitidis Semen group were higher than those of the normal control group, and lower than those of the model control group (P<0. 01 or P<0. 05). Conclusion Pharbitidis Semen can reduce NDEA-induced injury to the liver cells, and inhibit the overgrowth of the hepatoma.